Rapid tests for the qualitative detection of SARS-CoV-2 antigen.

The New Coronavirus 2019-nCoV Antigen Test, produced by Beijing Hotgen Biotech Co., Ltd, is a qualitative immunochromatographic test for the direct detection of SARS-CoV-2 proteins in nasopharyngeal secretions.

The test is highly accurate in diagnosing samples (sensitivity: 95.65%, specificity: 99.02%, accuracy: 97.89%), the results are obtained in 15 minutes and can be used both in first-line diagnosis (screening, rapid triage of patients, ambulatory testing), as well as individually, being easy to interpret.

Taking care and respecting the employees and the community, REMEDIA offers free tests to both its own employees and gymnasts from the National Sports College “Cetate” Deva, for safety training and sports competitions.

REMEDIA remains active in identifying innovative solutions and implementing processes aligned with international standards in health services.

The company will continue to comply with its obligations to inform shareholders / investors regarding any relevant information.

President of the Board of Administrators

„TARUS” – Valentin Norbert TARUS e.U.

Share this post
Share on facebook
Share on twitter
Share on linkedin

Related news

PRESS RELEASE

In compliance with the legal provisions in force on issuers and securities operations, the Board of Administrators of the Commercial Company Farmaceutica REMEDIA S.A. informs

2020 Nine Months Report

The Board of Directors of Farmaceutica REMEDIA S.A. informs that the Report for the 3rd Quarter of 2020, consolidated – the full version – is